RxDoctor Payments Data

Anita Campbell, MD

Glaucoma Specialist · Wichita, KSNPI 1104141159

Payments from drug & device makers

$78,907in general payments, 2019–2025

Across 223 payments — averaging $353.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$66K
  • AbbVie$10K
  • Alcon$1K
  • Bausch & Lomb Americas Inc.$413
  • Aerie Pharmaceuticals, Inc.$284
  • Amgen$221
  • plus $498 from 13 others
$121,296in research payments, 2019–2025

Across 7 payments — averaging $17,328 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ocular Therapeutix, Inc.$112K
  • Sight Sciences, Inc.$10K

What the payments were for

  • Consulting fees$6,80025%
  • Speaking & faculty fees$13,70050%
  • Travel & lodging$2071%
  • Food & beverage$6,50924%
  • Education$400%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$261,744
Medicare patients
408
Services billed
1,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost116$37,051
VyzultaLatanoprostene Bunod71$26,125
RestasisCyclosporine20$15,391
CombiganBrimonidine Tartrate/Timolol31$12,839
Prednisolone Acetate335$11,194
RocklatanNetarsudil Mesylat/Latanoprost22$7,439
RhopressaNetarsudil Mesylate14$6,811
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat340$4,339
Latanoprost608$3,664
Travoprost21$3,160
Dorzolamide-TimololDorzolamide/Timolol/Pf20$2,917
Brimonidine Tartrate194$2,755
Difluprednate26$2,683
Ketorolac Tromethamine135$2,425
Ofloxacin227$2,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$10,092$65,281167 claims
Bausch & Lomb Americas Inc.Vyzulta$413$26,12571 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$284$14,25036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Kansason file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Wichita

Where these figures come from

Is this you, or does something look wrong? →